Last reviewed · How we verify
NCT03683966: MALTA-FABRY
MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study
trial in Rare Diseases in 30 participants. Status unknown.
31 December 2023
Quick facts
| Lead sponsor | Wuerzburg University Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 27 October 2017 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Germany |
Conditions studied
- Rare Diseases — all drugs for Rare Diseases →
- Fabry Disease — all drugs for Fabry Disease →
- Adherence, Medication — all drugs for Adherence, Medication →
- Quality of Life — all drugs for Quality of Life →
Sponsor
Wuerzburg University Hospital
Who can join
18 and older, any sex, with Rare Diseases or Fabry Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates adherence to the oral chaperone therapy migalastat in patients with Fabry disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Contemporary therapeutics and new drug developments for treatment of Fabry disease: a narrative review.
Oder D, Müntze J, Nordbeck P. · · 2021 · cited 4× · PMID 33968645 · DOI 10.21037/cdt-20-743
Verify or expand the search:
- PubMed search for NCT03683966
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Rare Diseases
Currently open trials in the same condition.
- NCT06595940 — Genetic Analysis of Uncommon Disease Presentations in Non-US Populations · recruiting
- NCT07247279 — Epidemiological Study of Treatment Approaches in AChR-Antibody Positive Generalized Myasthenia Gravis in Russia · recruiting
- NCT07102966 — Genetic Study to Determine the Cause of Birth Defects in Newborns in Texas · NA · recruiting
- NCT06856902 — BEhavioral and Adherence Model for Improving Quality, Health Outcomes and Cost-Effectiveness of healthcaRe · NA · recruiting
- NCT06926127 — Genomic Profiling of Genetic and Rare Diseases · NA · recruiting
Other Wuerzburg University Hospital trials
Trials by the same sponsor.
- NCT07084480 — Giant Cell Arteritis - Ways to Precision Medicine · recruiting
- NCT07040189 — Gustabor Phase 1 - AI-based Creation of a Nutritional Plan to Compensate for Chemotherapy-induced Taste Disorders · NA · not yet recruiting
- NCT06550908 — Training Physicians to Differentiate the Paris Classification Using Artificial Colon Polyp Images · NA · recruiting
- NCT07108569 — Ability of Physicians to Distinguish Real From Artificial Colon Polyp Images · NA · completed
- NCT06553326 — EndoStyle: Artificial Intelligence Image Transformation Tool for Colonoscopy · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03683966 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wuerzburg University Hospital
- Last refreshed: 11 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03683966.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing